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Introduction
Sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil
(Cialis®) are potent and selective PDE5 Inhibitors which
are used for the treatment of erectile dysfunction (ED).
The aim of this study was to evaluate the potential of
PDE5 inhibition for the treatment of benign prostate
hyperplasia (BPH) and lower urinary tract symptoms
(LUTS).
Material-methods
The mRNA expression of PDE5 was determined in rat tis-
sues of the lower urinary tract. To test the functional rele-
vance of the PDE5 expression, sildenafil, vardenafil, and
tadalafil were tested on pre-contracted isolated rat blad-
der, prostate and urethra strips. The in vivo efficacy was
tested in a partial bladder outlet obstruction (BOO)
model after acute and chronic treatment.
Results
PDE5 mRNA expression was found highest in the bladder,
followed by the urethra and prostate. Vardenafil dose-
dependently relaxed the bladder strip at 1 μM and 10 μM
by 30% and 75%, respectively. In the urethra 1 μM varde-
nafil caused a 60% relaxation and in the prostate 1 and 10
μM vardenafil caused a relaxation by 51% and 97%
respectively. The rank order of potency in the investigated
organ bath assays was vardenafil > sildenafil > tadalafil. In
the BOO model, a dose-dependent reduction of the NVC
by 29% and 57% was observed after bolus i.v. administra-
tion of 3 mg/kg and 10 mg/kg vardenafil respectively.
Sildenafil was effective in the same range, however tadala-
fil had no significant effect. In a 5 week chronic treatment
study 10 mg/kg/d vardenafil showed significant reduction
of NVCs in BOO of 47%.
Summary and conclusion
Our experiments showed that PDE5 is expressed in lower
urinary tract tissues, that PDE5 inhibitors induced signifi-
cant relaxation of these tissues and reduced the irritative
symptoms of BPH/LUTS in vivo. Therefore, PDE5 inhibi-
tors might be an effective treatment option of BPH/LUTS.
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